

06-27-05

15:31

From:CLARK & ELBING LLP

+6174287023

T-485 P.001/004 F-554

RECEIVED  
CENTRAL FAX CENTER

JUN 27 2005

# Clark & Elbing LLP

101 Federal Street  
Boston, MA 02110

Telephone 617-428-0200  
Facsimile 617-428-7045  
617-428-7046

Date: June 27, 2005

To: Kagnew H. Grebeyesus  
Art Unit 1652

Facsimile No: 571 273 2937

From: Karen L. Elbing, Ph.D.

Re: U.S. Application No. 10/715,632  
Attorney Docket No. 00398/518002

Pages: 1 Cover Sheet  
1 Submission of Declaration under 37 C.F.R. §§ 1.131 and 1.132  
2 Combined Declaration of Dr. Howard K. Surks and Dr. Michael E.  
Mendelsohn under 37 C.F.R. §§ 1.131 and 1.132

---

NOTICE: This facsimile transmission may contain confidential or privileged information intended for the addressee only. If you are not the addressee, be aware that any disclosure, copying, distribution, or use of the information is prohibited. If you have received this facsimile transmission in error, please call us at 617-428-0200 to arrange for its return at no cost to you.

---

06-27-05

15:31

From:CLARK &amp; ELBING LLP

+6174287023

T-485 P.002/004 F-554

## PATENT

ATTORNEY DOCKET NUMBER: 00398/518002

Certificate of Transmission: Date of Transmission: June 27, 2005

I hereby certify under 37 C.F.R. § 1.8(a) that this correspondence is being transmitted via facsimile on the date indicated above and is addressed to Kagne H. Gebreyesus, 571 273 2937, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Santa Zingariello

Printed name of person mailing correspondence

Santa Zingariello

Signature of person mailing correspondence

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Mendelsohn et al.

Art Unit: 1652

RECEIVED  
CENTRAL FAX CENTER

Serial No.: 10/715,632

Examiner: Gebreyesus, K.H.

JUN 27 2005

Filed: November 17, 2003

Customer No.: 21559

Title: COMPOSITIONS INVOLVING M-RIP, AND RELATED METHODS  
FOR SCREENING FOR ANTI-HYPERTENSIVE AGENTS, AND USES  
THEREOF


Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

SUBMISSION OF DECLARATION UNDER 37 C.F.R. §§ 1.131 and 1.132

As requested by the Office, enclosed is a Declaration under 37 C.F.R. §§ 1.131 and 1.132  
executed by both Applicants in the instant case.

Applicants submit that the claims are in condition for allowance, and such action is respectfully requested. If there are any charges or any credits, please apply them to Deposit Account No. 03-2095.

Respectfully submitted,

  
 Karen L. Elbing, Ph.D.  
 Reg. No. 35,238

Clark & Elbing LLP  
101 Federal Street  
Boston, MA 02110  
Telephone: 617-428-0200  
Facsimile: 617-428-7045

06-27-05 15:31

From:CLARK & ELBING LLP

+6174287023

T-485 P.003/004 F-554

RECEIVED  
CENTRAL FAX CENTER

JUN 27 2005

PATENT  
ATTORNEY DOCKET NO. 00398/518002

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Michael E. Mendelsohn et al. Art Unit: 1652  
Serial No.: 10/715,632 Examiner: K. H. Gebreyesus  
Filed: November 17, 2003 Customer No.: 21559  
Title: COMPOSITIONS INVOLVING M-RIP, AND RELATED METHODS FOR SCREENING FOR ANTI-HYPERTENSIVE AGENTS, AND USES THEREOF

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

COMBINED DECLARATION OF DR. HOWARD K. SURKS AND DR. MICHAEL E. MENDELSON UNDER 37 C.F.R. §§ 1.131 and 1.132

1. We are the inventors of the above-referenced patent application.
2. We have read the Office Action mailed November 4, 2004.
3. Any description of the above-referenced invention in Surks et al., J. Biol. Chem. 2003, 278:51484-51493 was our contribution alone, notwithstanding the inclusion of an additional author on the paper.
4. Claims 5, 6, and 9 stand rejected under 35 U.S.C. § 102(a) by Inazawa et al.

GenBank accession no. AB098507, which was published on June 21, 2003. The claimed invention was reduced to practice in the United States on or before May 12, 2003, as evidenced by the date of submission of SEQ ID NO: 19 of the instant application to GenBank (Exhibit A).

5. We hereby declare that all statements made herein of our own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patents issued thereon.

Date: 6/20/05



Dr. Howard K. Surks

Date: 6/19/05

  
\_\_\_\_\_  
Dr. Michael E. Mendelsohn